Efficacy of weekly mizoribine pulse therapy in refractory lupus nephritis

References

• Bertsias G, Boumpas DT. Lupus nephritis-winning a few battles but not the war. Nat Rev Rheumatol. 2011;7:441–2.
   PubMed Web of Science ®Google Scholar
• Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, Garrido Ed Ede R, Danieli MG, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophospha-mide. Arthritis Rheum. 2002;46:2121–31.
   Google Scholar
• Contreras G, Pardo V, Leclercq B, Lenz O, Toanan E, O'Nan P, Roth D. Sequential therapies for proliferative lupus nephritis. N Engl J Med. 2004;350:971–80.
   Google Scholar
• Ogawa H, Kameda H, Amano K, Takeuchi T. Efficacy and safety of cyclosporine A in patients with refractory systemic lupus erythematosus in a daily clinical practice. Lupus. 2010;19:162–9.
   PubMed Web of Science ®Google Scholar
• Ishikawa H. Mizoribine and mycophenolate mofetil. Curr Med Chem. 1999;6:575–97.
   PubMed Web of Science ®Google Scholar
• Houssiau FA, D'Cruz D, Sangle S, Remy P, Vasconcelos C, MAINTAIN Nephritis Trial Group, et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis. 2010;69:2083–9.
   Google Scholar
• Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Aspreva Lupus Management Study Group, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20: 1103–12.
   Google Scholar
• Sugitani A, Kitada H, Ota M, Yoshida J, Doi A, Hirakata H. Revival of effective and safe high-dose mizoribine for the kidney transplantation. Clin Transpl. 2006;20:590–5.
   Web of Science ®Google Scholar
• Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythe-matosus disease activity index 2000. J Rheumatol. 2002;29: 288–91.
   Google Scholar
• Hosotsubo H, Takahara S, Taenaka N. Simplified high-perfor-mance liquid chromatographic method for determination of mizoribine in human serum. J Chromatogr. 1988;432:340–5.
   Google Scholar
• Homma M, Akizuki M, Yokobari R, Hashimoto H, Kashiwazaki S, Kondo H, et al. Clinical evaluation of mizoribine on lupus nephritis. Rinsyo-Iyaku. 1989;5(4):795–824 (in Japanese).
   Google Scholar
• Kuroda T, Hirose S, Tanabe N, Sato H, Nakatsue T, Ajiro J, et al. Mizoribine therapy for patients with lupus nephritis: the associ-ation between peak mizoribine concentration and clinical effi-cacy. Mod Rheumatol. 2007;17:206–12.
   PubMedGoogle Scholar
• Sonda K, Takahashi K, Tanabe K, Funchinoue S, Hayasaka Y, Kawaguchi H, et al. Clinical pharmacokinetic study of mizoribine in renal transplantation patients. Transpl Proc. 1996;28:3643–8.
   PubMed Web of Science ®Google Scholar
• Turka LA, Dayton J, Sinclair G, Thompson CB, Mitchell BS. Guanine ribonucleotide depletion inhibits T cell activation. Mechanism of action of the immunosuppressive drug mizoribine. J Clin Invest. 1991;87:940–8.
   PubMed Web of Science ®Google Scholar
• Hirohata S, Nakanishi K, Yanagida T. Inhibition of cyclin A gene expression in human B cells by an immunosuppressant mizori-bine. Clin Exp Immunol. 2000;120:448–53.
   Google Scholar
• Takahashi S, Wakui H, Gustafsson JA, Zilliacus J, Itoh H. Func-tional interaction of the immunosuppressant mizoribine with the 14-3-3 protein. Biochem Biophys Res Commun. 2000;274: 87–92.
   Google Scholar
• Ishida K, Kaneda H, Uemura O, Ushijima K, Ohta K, Goto Y, et al. Evaluation of limited sampling designs to estimate maximal con-centration and area under the curve of mizoribine in pediatric patients with renal disease. Drug Metab Pharmacokinet. 2011;26:71–8.
   PubMed Web of Science ®Google Scholar
• Stypinski D, Obaidi M, Combs M, Weber M, Stewart AJ, Ishikawa H. Safety, tolerability and pharmacokinetics of high-dose mizoribine in healthy male volunteers. Br J Clin Pharmacol. 2006;63:459–68.
   PubMed Web of Science ®Google Scholar
• Yumura W, Uchida K, Kawashima A, Kobayashi H, Miwa N, Honda K et al. Evaluation of plasma concentration of mizoribine as an immunosuppressive agent in lupus nephritis patients. Kid-ney Dial. 1999;47:705-8. (in Japanese).
   Google Scholar
• Doi T, Masaki T, Shiraki N, Kawai T, Yorioka N. Oral mizori-bine pulse therapy for steroid-dependent focal segmental glo-merulosclerosis. Clin Nephrol. 2008;69:433–5.
   Google Scholar
• Tanaka H, Tsugawa K, Nakahata T, Kudo M, Suzuki K, Ito E. Implication of the peak serum level of mizoribine for control of the serum anti-dsDNA antibody titer in patients with lupus nephritis. Clin Nephrol. 2005;63:417–22.
   PubMed Web of Science ®Google Scholar
• Tanaka H, Tsugawa K, Old E, Suzuki K, Ito E. Long-term mizoribine intermittent pulse therapy for young patients with flare of lupus nephritis. Clin Rheumatol. 2008;27:85–9.
   Google Scholar
• Suzuki K, Kameda H, Amano K, Nagasawa H, Takei H, Nishi E, et al. Single center prospective study of tacrolimus efficacy and safety in the treatment of various manifestations of systemic lupus erythematosus. Rheumatol Int. 2011;31:757–63.
   PubMed Web of Science ®Google Scholar
• Bao H, Liu Z-H, Xie H-L, Hu W-X, Zhang H-T, Li L-S. Suc-cessful treatment of class V + IV lupus nephritis with multitarget therapy. J Am Soc Nephrol. 2008;19:2001–10.
   Google Scholar
• Aizawa-Yashiro T, Tsuruga K, Watanabe S, Old E, Ito E, Tanaka H. Novel multidrug therapy for children with cyclosporine-resistant or -intolerant nephrotic syndrome. Pediatr Nephrol. 2011;26:1255–61.
   Google Scholar